Radiance/Endologix Merger Combines AAA, Brachytherapy Pipelines
This article was originally published in The Gray Sheet
Executive Summary
Endologix will gain R&D funding for its PowerLink abdominal aortic aneurysm system through a combination with brachytherapy device developer Radiance Medical Systems. A definitive merger pact was announced Feb. 11
You may also be interested in...
Drug-Coated Stents Will Pay Their Way If Priced At $2,500 Or Below – Cohen
The ability of drug-eluting stents to reduce the need for revascularization procedures justifies a price premium of up to $1,500 over regular stents, according to a cost-efficiency model by cardiologist David Cohen, MD, Beth Israel Deaconess Medical Center
Novoste Outlines Plan To Weather Coming Flood Of Drug-Coated Stents
Novoste will acquire several new vascular intervention products to sustain its sales force in 2003 and 2004, when new drug-coated stents are expected to quell demand for the company's Beta-Cath coronary brachytherapy system, the firm reported Jan. 10 at the JP Morgan Healthcare Conference in San Francisco
J&J/Cordis Teramed Alliance Suggests Swifter Access To $1 Bil. AAA Market
Johnson & Johnson/Cordis will join a crowded field of players in the worldwide abdominal aortic aneurysm (AAA) market, expected to top $1 bil. by 2008, following the acquisition of privately-held Teramed